Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Total Current Liabilities (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Total Current Liabilities data on record, last reported at $290.4 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 77.18% year-over-year to $290.4 million; the TTM value through Dec 2025 reached $290.4 million, up 77.18%, while the annual FY2025 figure was $290.4 million, 77.18% up from the prior year.
  • Total Current Liabilities reached $290.4 million in Q4 2025 per RVMD's latest filing, up from $245.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $290.4 million in Q4 2025 and bottomed at $43.8 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $108.7 million, with a median of $81.8 million recorded in 2023.
  • The widest YoY moves for Total Current Liabilities: up 132.08% in 2023, down 4.91% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $60.4 million in 2021, then grew by 2.71% to $62.0 million in 2022, then soared by 132.08% to $143.9 million in 2023, then increased by 13.95% to $163.9 million in 2024, then skyrocketed by 77.18% to $290.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $290.4 million in Q4 2025, $245.6 million in Q3 2025, and $184.5 million in Q2 2025.